CN1398181A - 治疗炎性疾病的方法和组合物 - Google Patents

治疗炎性疾病的方法和组合物 Download PDF

Info

Publication number
CN1398181A
CN1398181A CN01804708A CN01804708A CN1398181A CN 1398181 A CN1398181 A CN 1398181A CN 01804708 A CN01804708 A CN 01804708A CN 01804708 A CN01804708 A CN 01804708A CN 1398181 A CN1398181 A CN 1398181A
Authority
CN
China
Prior art keywords
sodium
rolipram
pde4
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01804708A
Other languages
English (en)
Chinese (zh)
Inventor
伊丽莎白·T·基廷
詹姆斯·M·卡纳吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1398181A publication Critical patent/CN1398181A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN01804708A 2000-02-08 2001-02-08 治疗炎性疾病的方法和组合物 Pending CN1398181A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18087900P 2000-02-08 2000-02-08
US60/180,879 2000-02-08

Publications (1)

Publication Number Publication Date
CN1398181A true CN1398181A (zh) 2003-02-19

Family

ID=22662062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01804708A Pending CN1398181A (zh) 2000-02-08 2001-02-08 治疗炎性疾病的方法和组合物

Country Status (16)

Country Link
EP (1) EP1253919A4 (xx)
JP (1) JP2003522142A (xx)
KR (1) KR20020073577A (xx)
CN (1) CN1398181A (xx)
AU (1) AU7205701A (xx)
BR (1) BR0108087A (xx)
CA (1) CA2398184A1 (xx)
CZ (1) CZ20022682A3 (xx)
HK (1) HK1051319A1 (xx)
HU (1) HUP0300689A3 (xx)
IL (1) IL150963A0 (xx)
MX (1) MXPA02007688A (xx)
NO (1) NO20023737L (xx)
PL (1) PL356447A1 (xx)
WO (1) WO2001058441A1 (xx)
ZA (1) ZA200206252B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
PL210463B1 (pl) * 2001-09-19 2012-01-31 Nycomed Gmbh Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów
EP1463509A1 (en) * 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
WO2004098605A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Pharmaceutical composition comprising a pde4 inhibitor and il-1 trap
WO2005020926A2 (en) * 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
EP2400961B1 (de) * 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
EA022046B1 (ru) 2010-07-14 2015-10-30 Новартис Аг Гетероциклические соединения, агонисты рецептора ip
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
ES2637719T3 (es) 2013-02-13 2017-10-16 Novartis Ag Compuestos heterocíclicos agonistas del receptor IP

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061779A (en) * 1973-09-11 1977-12-06 Beecham Group Limited Naphthalene derivatives having anti-inflammatory activity
GB9108128D0 (en) * 1991-04-15 1991-06-05 Zambeletti Spa L Novel formulation
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
FR2753706B1 (fr) * 1996-09-20 1998-10-30 Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
HUP0300689A2 (hu) 2003-07-28
ZA200206252B (en) 2003-08-26
CA2398184A1 (en) 2001-08-16
HUP0300689A3 (en) 2003-09-29
HK1051319A1 (zh) 2003-08-01
MXPA02007688A (es) 2002-12-13
NO20023737L (no) 2002-09-27
BR0108087A (pt) 2002-10-29
KR20020073577A (ko) 2002-09-27
NO20023737D0 (no) 2002-08-07
CZ20022682A3 (cs) 2003-09-17
PL356447A1 (en) 2004-06-28
AU7205701A (en) 2001-08-20
EP1253919A1 (en) 2002-11-06
WO2001058441A1 (en) 2001-08-16
IL150963A0 (en) 2003-02-12
EP1253919A4 (en) 2007-03-14
JP2003522142A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
CN100475208C (zh) 高脂血症治疗药剂
CN1551763A (zh) 新颖的治疗方法
NZ527232A (en) A composition contaning a PDE 4 inhibitor and a beta adrenergic bronchodilator useful for treating pulmonary diseases
CN102526733A (zh) 用于预防心血管事件发病的组合物
CN1420768A (zh) 含有非甾类抗雄激素和egfr酪氨酸激酶抑制剂的联合产品
JPH07330628A (ja) 薬剤組成物及びこれを用いた治療法
EP1594499A1 (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
JP2007277267A (ja) （ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシヘプツ−６−エン酸と、ｐ４５０アイソザイム３ａ４の阻害剤、誘導剤又は基質を含んでなる薬物の組み合わせ
CN1398181A (zh) 治疗炎性疾病的方法和组合物
US20120244212A1 (en) Enhanced method and composition for the treatment of hiv+ tuberculosis patients with anti-retroviral drugs and liposomal encapsulation for delivery of reduced glutathione
CN101437503A (zh) 用于降低血糖水平和治疗糖尿病的组合物
CN1518460A (zh) 含有pde－4抑制剂和h1－受体拮抗剂的组合物,及其在制备用于治疗呼吸系统疾病的药物中的用途
Scherf-Clavel Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed
Clissold et al. Proquazone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states
US20040171593A1 (en) Method and compositions for treating an inflammatory disease
WO2001060358A1 (en) Method and compositions for treating fibrotic diseases
AU2004240185A1 (en) Method and compositions for treating an inflammatory disease
WO2005079811A1 (en) Improved therapy using a combination of raloxifene and alendronate
von Ehr et al. Pleiotropic Antithrombotic Effects of Cardiovascular Drugs
Jones Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor
CN103800902A (zh) 含有齐墩果酸的药物组合物及其医药用途
WO2007030107A1 (en) Combination therapy for treatment of high cholesterol
WO2024086312A1 (en) Enhanced nad+ compositions and methods of making and using the same
TW201927304A (zh) 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
reddy Challa et al. Gastric ULCER Prevention by Lansoprazole

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication